'Voranigo' for malignant brain tumor expected to land in KOR
By Eo, Yun-Ho | translator Hong, Ji Yeon
24.11.11 05:43:02
가나다라
0
Approval application has been filed…the drug's efficacy has been demonstrated through the INDIGO study
MFDS has granted ODD for treating paitens with glioma who have IDH mutation
▲Product photo of Voranigo.
'Voranigo,' a new therapy for malignant brain tumors in over twenty years, is anticipated to be brought to South Korea. Sources said that Servier has recently filed an approval application for Voranigo (vorasidenib). Earlier in September, the Ministry of Food and Drug Safety (MFDS) assigned Voranigo an Orphan Drug Designation (ODD).
Voranigo's indication is to treat diffuse gliomas with an isocitrate dehydrogenase (IDH) mutation. Voranigo targets patients with low-grade gliomas who are vulnerable to IDH1 or IDH2 mutations.
This drug is a bispecific inhibitor of IDH1/2, developed by multinational pharmaceutical company Servier. It targets glioma (astrocytoma or oligoden
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)